Abstract:Recent studies have expanded the known functions of cGAS–STING in inflammation to a role in cancer due to its participation in activating immune surveillance. In cancer cells, the cGAS–STING pathway can be activated by cytosolic dsDNA derived from genomic, mitochondrial and exogenous origins. The resulting immune-stimulatory factors from this cascade can either attenuate tumor growth or recruit immune cells for tumor clearance. Furthermore, STING-IRF3-induced type I interferon signaling can enforce tumor antigen presentation on dendritic cells and macrophages and thus cross-prime CD8 + T cells for antitumor immunity. Given the functions of the STING pathway in antitumor immunity, multiple strategies are being developed and tested with the rationale of activating STING in tumor cells or tumor-infiltrating immune cells to elicit immunostimulatory effects, either alone or in combination with a range of established chemotherapeutic and immunotherapeutic regimens. Based on the canonical molecular mechanism of STING activation, numerous strategies for inducing mitochondrial and nuclear dsDNA release have been used to activate the cGAS-STING signaling pathway. Other noncanonical strategies that activate cGAS-STING signaling, including the use of direct STING agonists and STING trafficking facilitation, also show promise in type I interferon release and antitumor immunity priming. Here, we review the key roles of the STING pathway in different steps of the cancer-immunity cycle and characterize the canonical and noncanonical mechanisms of cGAS-STING pathway activation to understand the potential of cGAS-STING agonists for cancer immunotherapy.

Activation of Stimulation of Interferon Genes (STING) Signal and Cancer Immunotherapy

Cell-to-cell communications of cGAS-STING pathway in tumor immune microenvironment.

cGAS-STING signaling pathway in gastrointestinal inflammatory disease and cancers

Strategies involving STING pathway activation for cancer immunotherapy: mechanism and agonists

Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies

cGAS-STING pathway in cancer biotherapy

The Function of cGAS-STING Pathway in Treatment of Pancreatic Cancer

Clinical applications of STING agonists in cancer immunotherapy: current progress and future prospects

The cGAS/STING Pathway: A Novel Target for Cancer Therapy

The multiple faces of cGAS-STING in antitumor immunity: prospects and challenges

Chemical Biology Perspectives on STING Agonists as Tumor Immunotherapy

Enhancing immunotherapy outcomes by targeted remodeling of the tumor microenvironment via combined cGAS-STING pathway strategies

STING-mediated DNA sensing in cancer immunotherapy

Mini-review: the distinct roles of STING signaling in tumor immunity-recent progress

cGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors

STING pathway as a cancer immunotherapy: Progress and challenges in activating anti-tumor immunity

Targeting STING signaling for the optimal cancer immunotherapy

Immune Regulation of the cGAS-STING Signaling Pathway in the Tumor Microenvironment and Its Clinical Application

Synthetic Enforcement of STING Signaling in Cancer Cells Appropriates the Immune Microenvironment for Checkpoint Inhibitor Therapy.

Novel Emerging Nano-Assisted Anti-Cancer Strategies Based on the STING Pathway

Nanoparticle‐Mediated STING Activation for Cancer Immunotherapy